Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects

被引:91
作者
Borodic, GE [1 ]
Acquadro, M
Johnson, EA
机构
[1] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02115 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia, Boston, MA 02114 USA
[3] Univ Wisconsin, Dept Food Microbiol & Toxicol, Inst Food Res, Madison, WI 53706 USA
关键词
blepharospasm; botulinum toxin; dystonia; facial pain; inflammation; Meige syndrome; migraine headache; movement disease; myofascial pain; tension headache; torticollis; trigeminal neuralgia; toxin formulation; toxin quality;
D O I
10.1517/13543784.10.8.1531
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Botulinum toxin (BTX) injections are a well-recognised therapeutic modality for the treatment of regional involuntary muscle disorders and recently BTX has been used for treatment of pain and inflammatory disorders. The primary purpose of this review is to discuss the mechanism of action of therapeutic BTX in light of both the traditional understanding of BTX pharmacological effects as well as new observations. The review will deal with clinical observations and relevant animal experimentation. The data and hypotheses presented are not only relevant to botulinum toxin technology but will certainly prove important in the basic mechanisms of some of the diseases where botulinum toxin has been successfully applied. BTX used clinically comprises botulinum neurotoxin (BoNT) complexed with non-toxic proteins. The non-toxic components of the BTX complexes stabilise the labile BoNT during purification and formulation as a therapeutic. The complex proteins may also have unrecognised clinical significance such as slowing diffusion in tissues or imparting stability. The mechanisms of BTX formulations acting on SNARE proteins are briefly reviewed providing a basis for BTX clinical applications. The potential for design of improved botulinum toxins and formulations is addressed.
引用
收藏
页码:1531 / 1544
页数:14
相关论文
共 93 条
[1]   TREATMENT OF MYOFASCIAL PAIN WITH BOTULINUM-A TOXIN [J].
ACQUADRO, MA ;
BORODIC, GE .
ANESTHESIOLOGY, 1994, 80 (03) :705-706
[2]   Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle [J].
Adler, M ;
Keller, JE ;
Sheridan, RE ;
Deshpande, SS .
TOXICON, 2001, 39 (2-3) :233-243
[3]  
Anichini M, 1997, REV RHUM, V64, P18
[4]  
AWAD EA, 1973, ARCH PHYS MED REHAB, V54, P449
[5]  
BAKER MK, 1999, P INT C BAS THER ASP
[6]   The long-term outcome of microvascular decompression for trigeminal neuralgia [J].
Barker, FG ;
Jannetta, PJ ;
Bissonette, DJ ;
Larkins, MV ;
Jho, HD .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (17) :1077-1083
[7]   SNARE proteins mediate lipid bilayer fusion [J].
Bock, JB ;
Scheller, RH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (22) :12227-12229
[8]   Botulinum toxin therapy, immunologic resistance, and problems with available materials [J].
Borodic, G ;
Johnson, E ;
Goodnough, M ;
Schantz, E .
NEUROLOGY, 1996, 46 (01) :26-29
[9]   BOTULINUM A TOXIN FOR SPASMODIC TORTICOLLIS - MULTIPLE VS SINGLE INJECTION POINTS PER MUSCLE [J].
BORODIC, GE ;
PEARCE, LB ;
SMITH, K ;
JOSEPH, M .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 1992, 14 (01) :33-37
[10]   HISTOLOGIC ASSESSMENT OF DOSE-RELATED DIFFUSION AND MUSCLE-FIBER RESPONSE AFTER THERAPEUTIC BOTULINUM-A TOXIN INJECTIONS [J].
BORODIC, GE ;
FERRANTE, R ;
PEARCE, LB ;
SMITH, K .
MOVEMENT DISORDERS, 1994, 9 (01) :31-39